This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    NCT01829568
Previous Study | Return to List | Next Study

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01829568
First received: April 9, 2013
Last updated: July 11, 2017
Last verified: July 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Study Completion Date: No date given
  Primary Completion Date: September 1, 2015 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):